Oxford Immunotec Global (OXFD) Shares Down 19%

Oxford Immunotec Global PLC (NASDAQ:OXFD) shares were down 19% during mid-day trading on Tuesday . The company traded as low as $11.02 and last traded at $11.39. Approximately 1,366,500 shares traded hands during mid-day trading, an increase of 194% from the average daily volume of 464,220 shares. The stock had previously closed at $14.06.

A number of research analysts recently issued reports on OXFD shares. Robert W. Baird reaffirmed a “buy” rating and issued a $20.00 price target on shares of Oxford Immunotec Global in a report on Wednesday, November 1st. BTIG Research set a $21.00 price objective on Oxford Immunotec Global and gave the stock a “buy” rating in a report on Tuesday, October 31st. Cowen reissued a “buy” rating and set a $19.00 price objective on shares of Oxford Immunotec Global in a report on Thursday, September 28th. BidaskClub raised Oxford Immunotec Global from a “sell” rating to a “hold” rating in a report on Friday, December 15th. Finally, Zacks Investment Research raised Oxford Immunotec Global from a “sell” rating to a “hold” rating in a report on Wednesday, October 4th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company’s stock. Oxford Immunotec Global has a consensus rating of “Hold” and an average target price of $19.75.

The firm has a market cap of $292.21, a price-to-earnings ratio of -5.55 and a beta of -0.09. The company has a quick ratio of 4.30, a current ratio of 4.72 and a debt-to-equity ratio of 0.38.

In other Oxford Immunotec Global news, Director Richard A. Sandberg sold 3,000 shares of the business’s stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $13.35, for a total transaction of $40,050.00. Following the completion of the sale, the director now directly owns 17,778 shares of the company’s stock, valued at approximately $237,336.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 8.11% of the company’s stock.

Institutional investors have recently bought and sold shares of the company. Voya Investment Management LLC grew its position in shares of Oxford Immunotec Global by 16.0% during the 2nd quarter. Voya Investment Management LLC now owns 13,345 shares of the company’s stock worth $224,000 after buying an additional 1,845 shares during the period. Alliancebernstein L.P. acquired a new position in shares of Oxford Immunotec Global during the 2nd quarter worth about $247,000. Asymmetry Capital Management L.P. acquired a new position in shares of Oxford Immunotec Global during the 2nd quarter worth about $273,000. The Manufacturers Life Insurance Company grew its position in shares of Oxford Immunotec Global by 8.8% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,631 shares of the company’s stock worth $313,000 after buying an additional 1,500 shares during the period. Finally, Rhumbline Advisers grew its position in shares of Oxford Immunotec Global by 9.1% during the 2nd quarter. Rhumbline Advisers now owns 24,500 shares of the company’s stock worth $412,000 after buying an additional 2,053 shares during the period. Institutional investors own 89.35% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Oxford Immunotec Global (OXFD) Shares Down 19%” was originally published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this report on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The correct version of this report can be read at https://www.com-unik.info/2018/01/09/oxford-immunotec-global-oxfd-shares-down-19.html.

Oxford Immunotec Global Company Profile

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.

Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit